Scores by kind of claim
Each kind of claim is scored on its own, out of 100: the share that held up, with the range it likely falls in. Fewer resolved claims give a wider range.
-
Factual claims
Statements about the present or the past, checked against the record: did they hold up?
67 61 73 -
Predictions
Statements about events outside the person's control, checked once they fell due: did they come true?
60 44 76 -
Promises
Commitments to the person's or organisation's own future action, with something to deliver: was it delivered?
Insufficient record: 0 promises resolved, 5 needed for a score.
All types combined: 66 (likely 61 to 72, high confidence), from 105 claims: 94 factual claims, 11 predictions. It mixes kinds of claim in different proportions for different people, so compare people kind by kind.
Marc Andreessen's claims
19 claims
“Technological innovation in a market system is inherently philanthropic, by a 50:1 ratio.”
Marc Andreessen, a16z co-founder, author of manifesto 16 October 2023 The Techno-Optimist Manifesto (a16z)
In a market system, society captures about 98% of the value of technological innovation, a 50:1 ratio to the innovating company's share.
Mixed Partly true and partly false in roughly equal measure.
The second judge said mostly false; the verdict shown is the first judge's.
Said for an organisation they lead or work for; it counts on both records.
What would count as true or false
The claim rests on the estimate that innovators capture about 2% of the value of their innovations and society about 98% (a ratio of about 50:1). True: credible economic research (for example, William Nordhaus's 2004 NBER paper 'Schumpeterian Profits in the American Economy') estimates that innovators capture roughly 2% of the social returns to technological innovation in a market economy, and this finding is broadly accepted as a general estimate. Mostly true: research supports a figure close to this (innovators capturing roughly 1–4%, a ratio of about 25:1 to 100:1), or the figure comes from one widely cited estimate that is not contested. Mixed: estimates vary widely, some near 2% and others far off, so the 50:1 ratio is one plausible value among several. Mostly false: the figure comes from a single study but is stated as a universal law ('inherently'), or it applies only to a narrow period, sector or measure that the claim generalises. False: research shows that innovators typically capture a large share of the value of innovation (for example, more than 10%), or no economic research supports anything near 50:1.
Evidence
- The Price of a Cure: Luxturna and the Economic Dilemmas of Precision Medicine | Journal of Law, Medicine & Ethics | Cambridge Core Cambridge Core (Journal of Law, Medicine & Ethics)
“Consistent with this disease-specific result, Nordhaus estimates that innovators captured only about 2.2 percent of the total surplus generated by innovation in the US nonfarm business sector from 1948 to 2001.”
- Kalil_2006-08_LINKY.indd The Hamilton Project (Brookings Institution) · December 2006
“captured only 2.2 percent of the total value of their innovations during the period 1948–2001.”
- The Price of a Cure: Luxturna and the Economic Dilemmas of Precision Medicine | Journal of Law, Medicine & Ethics | Cambridge Core Cambridge Core (Journal of Law, Medicine & Ethics)
“Philipson and Jena estimate that producers captured only about 5 percent of the nearly $1.4 trillion in social surplus generated by HIV/AIDS therapies.”
- [PDF] RATE OF RETURN TO INVESTMENT IN R&D - Frontier Economics Frontier Economics (report for the UK Department for Science, Innovation and Technology) · March 2023
“Overall our best estimate is that the average private rate of return to R&D is at least 14% but is likely to be higher.”
Reasoning
E1 and E2 (independent sources) attribute to Nordhaus an estimate that innovators captured about 2.2% of the value of innovation, which matches the claimed ratio of about 50:1. That estimate covers only the US nonfarm business sector from 1948 to 2001. The only other estimate given (E3) finds producers captured about 5% of the surplus from HIV/AIDS therapies, a ratio of roughly 20:1. That figure points the same way but falls outside the 25:1–100:1 range. The evidence therefore supports a low share captured by innovators, but the exact 50:1 figure rests on one period-specific study, which the claim presents as an inherent feature of market systems; E4 measures rates of return on R&D and does not test the claimed split.
Cite this claim
Marc Andreessen, “In a market system, society captures about 98% of the value of technological innovation, a 50:1 ratio to the innovating company's share.” (said 16 October 2023). Verdict: mixed. Reliability API, claim c_adc8310eb7db, method 0.1.0+c876030c. https://epistacklabs.com/claims/c_adc8310eb7db
Claims without a verdict
Is a verdict here wrong, or do you speak for Marc Andreessen? Reply on the claim's own page, with the form at its foot (how replies work). Verdicts are made automatically; how verdicts and scores are made.